Ian M McElree
Overview
Explore the profile of Ian M McElree including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Annapureddy D, Taylor J, Kamat A, ODonnell M, Howard J, Tan W, et al.
Eur Urol Focus
. 2025 Feb;
PMID: 39922753
Background And Objective: Current data on bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) do not differentiate outcomes by clinical stage. The purpose of this study is to investigate the role...
2.
McElree I, Packiam V, Steinberg R, Hougen H, Chakra M, Mott S, et al.
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766026
After first-line treatment failure, patients with non-muscle invasive urothelial carcinoma (NMIUC) are recommended to undergo radical cystectomy. However, those unable to pursue radical surgery or desiring bladder preservation require effective...
3.
Taylor J, Kamat A, Annapureddy D, Khene Z, Howard J, Tan W, et al.
Eur Urol Oncol
. 2024 Dec;
PMID: 39694798
Background And Objective: Non-muscle-invasive bladder cancer (NMIBC) patients treated with additional bacillus Calmette-Guérin (BCG) may become unresponsive to BCG. Recently, sequential intravesical gemcitabine and docetaxel (gem/doce) are being used for...
4.
Chakra M, Packiam V, McElree I, Mott S, ODonnell M
Urol Oncol
. 2024 Nov;
PMID: 39592360
Background: The European Association of Urology (EAU) recommends early radical cystectomy (RC) for very-high-risk (VHR) nonmuscle invasive bladder cancer (NMIBC), in part due to suboptimal efficacy from BCG in this...
5.
Chakra M, Bailly H, Klampke F, Boaz J, Jida M, Abou Yassine A, et al.
Asian J Urol
. 2024 Nov;
11(4):530-544.
PMID: 39534008
Objective: This systematic review aimed to analyze animal and human trial data to better understand the efficacy of stem cell therapy (SCT) for erectile dysfunction (ED) and the obstacles that...
6.
McElree I, Packiam V, Steinberg R, Hougen H, Mott S, Chakra M, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061200
Growing evidence suggests that many patients with high-risk non-muscle invasive urothelial carcinoma (NMIUC) can undergo bladder-sparing management with salvage intravesical therapies. However, inherent or developed disease resistance, particularly after multiple...
7.
Chakra M, McElree I, Packiam V, Mott S, ODonnell M
Urol Oncol
. 2024 May;
42(9):289.e13-289.e21.
PMID: 38796357
Background: Guidelines lack clear recommendations regarding conservative management of micropapillary (MP) variant non-muscle invasive bladder cancer (NMIBC). Bladder-sparing therapy using intravesical Bacillus Calmette-Guerin (BCG) has been reported although there are...
8.
McElree I, Mott S, Hougen H, Packiam V, ODonnell M, Steinberg R
Urol Oncol
. 2024 Apr;
42(7):221.e9-221.e16.
PMID: 38609747
Introduction: Nephroureterectomy is commonly performed for high-grade (HG) upper tract (UT) urothelial carcinoma (UC). However, some patients may benefit from a de-escalation of surgical management, particularly for noninvasive disease and...
9.
Leyderman M, McElree I, Nepple K, Zakharia Y, Ghodoussipour S, Packiam V
Cureus
. 2024 Apr;
16(3):e55565.
PMID: 38576641
Renal cell carcinoma (RCC) tends to undergo intravascular tumor growth along the renal vein, forming tumor thrombi that may extend into the inferior vena cava (IVC) or even the right...
10.
Chakra M, Packiam V, Duquesne I, Peyromaure M, McElree I, ODonnell M
Expert Opin Pharmacother
. 2024 Jan;
25(2):203-214.
PMID: 38264853
Introduction: The combination of intravesical gemcitabine (Gem) with docetaxel (Doce) or with mitomycin C (MMC) has been used in the primary setting as an alternative to Bacillus Calmette-Guerin (BCG) to...